News & Updates

Show Multimedia Only

Supporting long-term HIV treatment success: Real-world durability of B/F/TAF

18 Sep 2026 by

Advances in antiretroviral therapy (ART) have transformed HIV management, with life expectancy among people living with HIV (PLHIV) now comparable to that of the general population. This makes choosing a durable regimen that can sustain treatment success over the long term increasingly important. Recent real-world evidence highlights the durability of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), an integrase strand transfer inhibitor (INSTI)–based three-drug regimen, in both treatment-naïve and treatment-experienced settings.

Supporting long-term HIV treatment success: Real-world durability of B/F/TAF

18 Sep 2026

Optimizing tolvaptan use in ADPKD

08 Sep 2026 by

Autosomal dominant polycystic kidney disease (ADPKD) – one of the leading causes of end-stage renal disease (ESRD) – is associated with various extrarenal manifestations. Timely intervention is crucial for slowing renal function decline in rapid progressors. At the Hong Kong Medical Forum (HKMF) 2026, Professor Yong-Chul Kim from the Division of Nephrology, Seoul National University Hospital, South Korea, shared his country’s approach to patient education in ADPKD and discussed the role of tolvaptan, a vasopressin V2- receptor antagonist, in disease management, highlighting evidence from clinical trials and real-world studies.

Optimizing tolvaptan use in ADPKD

08 Sep 2026

Recognizing the clinical interplay between CKD, COPD & HF: Case discussion & practical insights

07 Sep 2026 by

Chronic obstructive pulmonary disease (COPD) is increasingly recognized to be closely linked to cardiovascular-kidney-metabolic (CKM) conditions. As the population ages, patients with multiple comorbidities, including CKM syndrome and COPD, are commonly encountered in clinical practice across multiple specialties. A more coordinated effort and enhanced awareness are required for better management and outcome. At a symposium organized by the Federation of Medical Societies of Hong Kong (FMSHK) chaired by Dr Samuel Ka-Shun Fung, Executive Committee Member of FMSHK, Dr Ka-Chun Leung, Specialist in Nephrology of Tuen Mun Hospital, Dr Emmanuel Chun-Ka Wong of the Division of Cardiology, University of Hong Kong, and Dr Fanny Wai-San Ko of the Division of Respiratory Medicine, the Chinese University of Hong Kong, discussed how evolving multiorgan dysfunction, overlapping clinical presentations, and sequential treatment decisions shape diagnosis and management of these conditions. A case discussion of progression from chronic kidney disease (CKD) to worsening COPD and, subsequently, heart failure (HF) highlighted diagnostic and therapeutic complexities, and provided practice insights.

Recognizing the clinical interplay between CKD, COPD & HF: Case discussion & practical insights

07 Sep 2026

Use of insulin glargine U300 to improve glycaemic control in type 2 diabetes

28 Aug 2026 by

A 66-year-old female with a 20-year history of type 2 diabetes (T2D) presented with suboptimal glycaemic control. Her comorbidities included minor coronary artery disease, metabolic dysfunction–associated steatotic liver disease (MASLD), and chronic hepatitis B (HBV) carrier status. She had a body mass index (BMI) of 34.7 kg/m², blood pressure (BP) of 132/56 mm Hg, and LDL-cholesterol (LDL-C) level of 1.5 mmol/L.

Use of insulin glargine U300 to improve glycaemic control in type 2 diabetes

28 Aug 2026

Real-world insights: Optimizing patient selection for anti–IL-5 therapy to enhance CRSwNP control

26 Aug 2026 by

Severe, type 2 (T2)–driven chronic rhinosinusitis with nasal polyps (CRSwNP) commonly co-occurs with other T2 inflammation–related conditions such as eosinophilic asthma and aspirin-exacerbated respiratory disease (AERD; Samter’s triad). Its management often lies at the interface of Ear, Nose and Throat (ENT) and Respiratory Medicine. At a symposium organized by the Hong Kong College of Otorhinolaryngologists, three local and international experts shared real-world (RW) insights on multidisciplinary care pathways, as well as the effectiveness and strategic use of biologics with a focus on anti–interleukin (IL)-5 therapy (eg, mepolizumab), in achieving steroid- and surgery-free disease control.

Real-world insights: Optimizing patient selection for anti–IL-5 therapy to enhance CRSwNP control

26 Aug 2026

Optimizing management of multidrug-resistant MBL-producing GN infections

20 Aug 2026 by

Antimicrobial resistance among Gram-negative (GN) bacteria is an urgent global challenge. Infections caused by metallo-β-lactamase (MBL)–producing Enterobacterales and Stenotrophomonas maltophilia are of particular concern due to limited treatment options and high mortality. At an industry-sponsored symposium at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global 2026, infectious disease experts discussed emerging treatment strategies to improve outcomes, with a focus on the β-lactam/β-lactamase inhibitor combination, aztreonam-avibactam (ATM/AVI).

Optimizing management of multidrug-resistant MBL-producing GN infections

20 Aug 2026

Quizartinib improves survival across FLT3-ITD AML treatment phases and beyond

20 Aug 2026 by

The emergence of FLT3 inhibitors has reshaped the management of patients with acute myeloid leukaemia (AML) with FLT3-internal tandem duplication (ITD) mutations. At an industry-sponsored symposium during The Second Asia Pacific Myeloid Forum (APMF 2026), Professor Adriano Venditti of the University of Rome Tor Vergata in Rome, Italy, discussed the evolving treatment landscape for AML, detailing pivotal results of the QuANTUM-First trial and the potential of the oral, second-generation, type 2 FLT3 inhibitor, quizartinib, to extend survival benefits across all phases of AML therapy and beyond the FLT3-ITD mutation into the wild-type (WT) setting.

Quizartinib improves survival across FLT3-ITD AML treatment phases and beyond

20 Aug 2026

Achieving transfusion independence with first-line luspatercept in a patient with LR-MDS–associated anaemia

18 Aug 2026 by

An 84-year-old man presented with a 2-year history of chronic anaemia (haemoglobin [Hb], 10–11 g/dL) in December 2024. His anaemia progressively worsened, with Hb dropping to a nadir of 7.5 g/dL. He reported stable angina and reduced exercise tolerance, with an ability to walk only on level ground and inability to climb stairs. His medical history included ischaemic heart disease, hypertension, hypothyroidism, and mild cytopenia.

Achieving transfusion independence with first-line luspatercept in a patient with LR-MDS–associated anaemia

18 Aug 2026

[Infographics] ARNI for hypertension: Clinical trial data & Asian guideline recommendations

18 Aug 2026 by

The Japanese Society of Hypertension Guidelines 2025 recommend angiotensin receptor–neprilysin inhibitor (ARNI) as step 2 or step 3 treatment, highlighting its role in hypertension management in patients with comorbidities, including cardiac hypertrophy, chronic kidney disease and heart failure. Data from clinical trials, including those conducted in Asians, support these recommendations.

[Infographics] ARNI for hypertension: Clinical trial data & Asian guideline recommendations

18 Aug 2026

Expert insights into overcoming diagnostic hurdles and advancing management of HFpEF

14 Aug 2026 by

As heart failure with preserved ejection fraction (HFpEF) increasingly impacts global health, clinicians face distinct challenges in its identification and therapeutic approaches. At an expert meeting chaired by Professor Hung-Fat Tse of the School of Clinical Medicine, the University of Hong Kong, a panel of local cardiologists shared insights into effective and accurate HFpEF diagnosis in clinical practice, alongside strategies for its prevention and treatment.

Expert insights into overcoming diagnostic hurdles and advancing management of HFpEF

14 Aug 2026

News & Updates

Showing Multidisciplinary articles

Showing

Specialty:

Supporting long-term HIV treatment success: Real-world durability of B/F/TAF

Supporting long-term HIV treatment success: Real-world durability of B/F/TAF

Optimizing tolvaptan use in ADPKD

Optimizing tolvaptan use in ADPKD

Recognizing the clinical interplay between CKD, COPD & HF: Case discussion & practical insights

Recognizing the clinical interplay between CKD, COPD & HF: Case discussion & practical insights

Use of insulin glargine U300 to improve glycaemic control in type 2 diabetes

Use of insulin glargine U300 to improve glycaemic control in type 2 diabetes

Real-world insights: Optimizing patient selection for anti–IL-5 therapy to enhance CRSwNP control

Real-world insights: Optimizing patient selection for anti–IL-5 therapy to enhance CRSwNP control

Optimizing management of multidrug-resistant MBL-producing GN infections

Optimizing management of multidrug-resistant MBL-producing GN infections

Quizartinib improves survival across FLT3-ITD AML treatment phases and beyond

Quizartinib improves survival across FLT3-ITD AML treatment phases and beyond

Achieving transfusion independence with first-line luspatercept in a patient with LR-MDS–associated anaemia

Achieving transfusion independence with first-line luspatercept in a patient with LR-MDS–associated anaemia

[Infographics] ARNI for hypertension: Clinical trial data & Asian guideline recommendations

[Infographics] ARNI for hypertension: Clinical trial data & Asian guideline recommendations

Expert insights into overcoming diagnostic hurdles and advancing management of HFpEF

Expert insights into overcoming diagnostic hurdles and advancing management of HFpEF